Business
The company plans to divest a drug it has made for 40 years, citing increasing production costs and falling prices.
FEATURED STORIES
The necessity of delivering medicine days after it’s produced drives decisions about where to build facilities and how to ship radioactive materials to healthcare providers.
The first gene therapies approved to treat sickle cell disease in December 2023 are struggling on the market. But there are glimpses of forward momentum as Vertex and Genetix Bio provide updates.
Maintaining America’s momentum demands that policymakers resist policies that undermine research and development incentives.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
After reviewing its mid-pandemic performance, it became clear that its greatest challenge is around the handling of data, according to Amy P. Abernethy, M.D., Ph.D., principal deputy commissioner, FDA, speaking at the recent Demy-Colton Virtual Salon, the “Fusion of Technologies.”
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
It’s a day of firsts, with the launch of two new Cambridge, Mass.-based life sciences companies.
Roche and Atea Pharmaceuticals are partnering to develop, manufacture and distribute AT-527, Atea’s experimental antiviral drug against COVID-19.
Finding and developing an effective treatment for nonalcoholic steatohepatitis has, so far, been met with as much futility and frustration as developing a treatment for Alzheimer’s disease. Sagimet Biosciences Chief Executive Officer George Kemble believes his company is on the right path, though.
October is Breast Cancer Awareness month, and Daiichi Sankyo is aiming to raise awareness about one of the most common forms of cancer across the globe.
As we resign ourselves to the fact that the epic SARS-CoV-2 virus that dominated 2020 is going to stubbornly follow us into 2021, we need to learn how to co-exist in temporary tolerance, at least until we have an effective vaccine.
Kite, a Gilead company, is building a franchise, not just a brand, on the promise of its CAR-T cell therapies.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 20, 2020.
Under terms of the Korsuva deal, Connecticut-based Cara Therapeutics will receive $100 million in an upfront payment, as well as an equity investment of $50 million. Additional milestone payments could bring the total of the deal to about $290 million.